HRA003285
Title:
A randomized, phase 2 GUIDANCE-01 trial
Release date:
2023-09-03
Description:
Genetic subtypes of diffuse large B-cell lymphoma (DLBCL) have variable oncogenic alterations and clinical outcomes. We conducted a randomized, phase 2 GUIDANCE-01 trial of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) alone, or with targeted agents guided by genetic subtypes (R-CHOP-X, MCD-like and BN2-like with ibrutinib, N1-like and NOS with lenalidomide, EZB-like with tucidinostat, and TP53mut with decitabine) in newly diagnosed, intermediate-risk or high-risk DLBCL.
Data Accessibility:   
Controlled access Request Data
BioProject:
Study type:
Disease Study
Disease name:
diffuse large B-cell lymphoma
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
DAC name:
DAC for GUIDANCE-01 trial
Contact person:
Tian Shuang
Email:
tianshuang.j@foxmail.com
Description:
This project includes WGS and RNA-sequencing data for DLBCL patients
Individuals & samples
Submitter:   Zhao Weili / zhaoweili_sih@163.com
Organization:   Shanghai Institute of Hematology, Shanghai Jiaotong University School of Medicine
Submission date:   2022-09-28
Requests:   1